Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:55 2026-04-20 am EDT			5-day change	1st Jan Change
118.22 ^CHF	-0.50%		-1.99%	+7.86%

Apr. 20	Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma	RE
Apr. 15	Tango Therapeutics, Inc. Announces Leadership Appointments	CI

NOVARTIS AG : Berenberg remains Neutral

Published on 03/06/2026 at 06:11 am EST

MarketScreener with dpa-AFX Analyser

NOVARTIS AG

-0.50%

Berenberg confirms his opinion on the stock and remains Neutral. The target price has been raised from CHF 92 to CHF 110.

Latest news about Novartis AG

Apr. 20	Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma	RE
Apr. 15	Tango Therapeutics, Inc. Announces Leadership Appointments	CI
Apr. 15	Novartis CEO joins Anthropic board of directors
Apr. 15	Swiss stocks - Factors to watch on April 15	RE
Apr. 14	Xspray Pharma's Proposed Proprietary Name for Myeloid Leukemia Drug Gets US FDA Nod	MT
Apr. 14	Anthropic adds Novartis CEO Vas Narasimhan to its board	RE
Apr. 14	Betting on Restraint
Apr. 14	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
Apr. 14	The V for victory, at least on the charts
Apr. 13	US FDA expands approval for Travere's drug for rare kidney disease	RE
Apr. 10	Health Care Down on Retreat from Biotech -- Health Care Roundup	DJ
Apr. 10	NOVARTIS AG : UBS reiterates its Neutral rating	ZD
Apr. 09	European Stocks Mostly Lower in Thursday Trading; Oil Prices Rise as Ceasefire on Shaky Ground	MT
Apr. 09	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Fragile Middle East Ceasefire Lifts Oil Prices	MT
Apr. 09	Novartis to Expand Community Health Programs to More Countries	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Apr. 28 - Earnings release - Q1 2026

More about the company